Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: Current evidence and study protocol for a randomized trial

Trials

Volumn 14, Issue 1, 2013, Pages

  Kim, Suk J ^a   Moon, Gyeong J ^a,b   Chang, Won H ^a   Kim, Yun Hee ^a   Bang, Oh Y ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Cerebral infarction; Clinical trial; Mesenchymal stem cells; Neurogenesis; Stem cells; Stroke

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; ISCHEMIC PRECONDITIONING; MAJOR CLINICAL STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAFETY; SINGLE BLIND PROCEDURE; STROKE PATIENT;

ACUTE DISEASE; CELLS, CULTURED; CHRONIC DISEASE; CLINICAL PROTOCOLS; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RESEARCH DESIGN; SERUM; STROKE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84884788312     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-14-317     Document Type: Article

References (65)

1. Hong KS, Ali LK, Selco SL, Fonarow GC, Saver JL. Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years. Stroke 2011, 42:1722-1729. 10.1161/STROKEAHA.110.600106, 3109505, 21527766.
2. Savitz SI, Dinsmore J, Wu J, Henderson GV, Stieg P, Caplan LR. Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts: a preliminary safety and feasibility study. Cerebrovasc Dis 2005, 20:101-107.
3. Sprigg N, Bath PM, Zhao L, Willmot MR, Gray LJ, Walker MF, Dennis MS, Russell N. Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke: the stem cell trial of recovery enhancement after stroke (STEMS) pilot randomized, controlled trial (ISRCTN 16784092). Stroke 2006, 37:2979-2983. 10.1161/01.STR.0000248763.49831.c3, 17082474.
4. Savitz SI, Misra V, Kasam M, Juneja H, Cox CS, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 2011, 70:59-69. 10.1002/ana.22458, 21786299.
5. Friedrich MA, Martins MP, Araujo MD, Klamt C, Vedolin L, Garicochea B, Raupp EF, Sartori E, Ammar J, Machado DC, Costa JC, Nogueira RG, Rosado-de-Castro PH, Mendez-Otero R, Freitas GR. Intra-arterial infusion of autologous bone marrow mononuclear cells in patients with moderate to severe middle cerebral artery acute ischemic stroke. Cell Transplant 2012, 21(Suppl 1):S13-S21.
6. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005, 57:874-882. 10.1002/ana.20501, 15929052.
7. Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010, 28:1099-1106. 10.1002/stem.430, 20506226.
8. Honmou O, Houkin K, Matsunaga T, Niitsu Y, Ishiai S, Onodera R, Waxman SG, Kocsis JD. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 2011, 134:1790-1807. 10.1093/brain/awr063, 3102237, 21493695.
9. Bhasin A, Srivastava MV, Kumaran SS, Mohanty S, Bhatia R, Bose S, Gaikwad S, Garg A, Airan B. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra 2011, 1:93-104. 10.1159/000333381, 3343764, 22566987.
10. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants Stem cell therapies as an emerging paradigm in stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 2009, 40:510-515. Stem Cell Therapies as an Emerging Paradigm in Stroke Participants.
11. Dorman PJ, Sandercock PA. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke 1996, 27:1507-1515. 10.1161/01.STR.27.9.1507, 8784121.
12. Lees JS, Sena ES, Egan KJ, Antonic A, Koblar SA, Howells DW, Macleod MR. Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis. Int J Stroke 2012, 7:582-588. 10.1111/j.1747-4949.2012.00797.x, 22687044.
13. Hermann DM, Chopp M. Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol 2012, 11:369-380. 10.1016/S1474-4422(12)70039-X, 22441198.
14. Zhang R, Zhang Z, Wang L, Wang Y, Gousev A, Zhang L, Ho KL, Morshead C, Chopp M. Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. J Cereb Blood Flow Metab 2004, 24:441-448.
15. Kokaia Z, Thored P, Arvidsson A, Lindvall O. Regulation of stroke-induced neurogenesis in adult brain-recent scientific progress. Cereb Cortex 2006, 16(Suppl 1):i162-i167.
16. Darsalia V, Heldmann U, Lindvall O, Kokaia Z. Stroke-induced neurogenesis in aged brain. Stroke 2005, 36:1790-1795. 10.1161/01.STR.0000173151.36031.be, 16002766.
17. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002, 8:963-970. 10.1038/nm747, 12161747.
18. Li WY, Choi YJ, Lee PH, Huh K, Kang YM, Kim HS, Ahn YH, Lee G, Bang OY. Mesenchymal stem cells for ischemic stroke: changes in effects after ex vivo culturing. Cell Transplant 2008, 17:1045-1059. 10.3727/096368908786991551, 19177841.
19. Yamashita T, Ninomiya M, Hernandez Acosta P, Garcia-Verdugo JM, Sunabori T, Sakaguchi M, Adachi K, Kojima T, Hirota Y, Kawase T, Araki N, Abe K, Okano H, Sawamoto K. Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. J Neurosci 2006, 26:6627-6636. 10.1523/JNEUROSCI.0149-06.2006, 16775151.
20. Chopp M, Li Y. Treatment of neural injury with marrow stromal cells. Lancet Neurol 2002, 1:92-100. 10.1016/S1474-4422(02)00040-6, 12849513.
21. Abrahams JM, Gokhan S, Flamm ES, Mehler MF. De novo neurogenesis and acute stroke: are exogenous stem cells really necessary?. Neurosurgery 2004, 54:150-155. 10.1227/01.NEU.0000097515.27930.5E, 14683552.
22. Lindvall O, Kokaia Z. Recovery and rehabilitation in stroke: stem cells. Stroke 2004, 35:2691-2694. 10.1161/01.STR.0000143323.84008.f4, 15459434.
23. Bang OY, Park HY, Yoon JH, Yeo SH, Kim JW, Lee MA, Park MH, Lee PH, Joo IS, Huh K. Predicting the long-term outcome after subacute stroke within the middle cerebral artery territory. J Clin Neurol 2005, 1:148-158. 10.3988/jcn.2005.1.2.148, 2854920, 20396462.
24. Gilman S. Time course and outcome of recovery from stroke: relevance to stem cell treatment. Exp Neurol 2006, 199:37-41. 10.1016/j.expneurol.2005.12.003, 16427047.
25. Hill WD, Hess DC, Martin-Studdard A, Carothers JJ, Zheng J, Hale D, Maeda M, Fagan SC, Carroll JE, Conway SJ. SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury. J Neuropathol Exp Neurol 2004, 63:84-96.
26. Shen LH, Li Y, Chen J, Zacharek A, Gao Q, Kapke A, Lu M, Raginski K, Vanguri P, Smith A, Chopp M. Therapeutic benefit of bone marrow stromal cells administered 1 month after stroke. J Cereb Blood Flow Metab 2007, 27:6-13. 10.1038/sj.jcbfm.9600311, 16596121.
27. Misra V, Ritchie MM, Stone LL, Low WC, Janardhan V. Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy. Neurology 2012, 79:S207-S212. 10.1212/WNL.0b013e31826959d2, 23008400.
28. Hess DC, Borlongan CV. Cell-based therapy in ischemic stroke. Expert Rev Neurother 2008, 8:1193-1201. 10.1586/14737175.8.8.1193, 2753686, 18671663.
29. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, et al. Heart disease and stroke statistics - 2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2009, 119:e21-e181.
30. Dihne M, Hartung HP, Seitz RJ. Restoring neuronal function after stroke by cell replacement: anatomic and functional considerations. Stroke 2011, 42:2342-2350. 10.1161/STROKEAHA.111.613422, 21737804.
31. Kawai H, Yamashita T, Ohta Y, Deguchi K, Nagotani S, Zhang X, Ikeda Y, Matsuura T, Abe K. Tridermal tumorigenesis of induced pluripotent stem cells transplanted in ischemic brain. J Cereb Blood Flow Metab 2010, 30:1487-1493. 10.1038/jcbfm.2010.32, 2949240, 20216552.
32. Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem cell therapy as an emerging paradigm for stroke (STEPS) II. Stroke 2011, 42:825-829.
33. Wechsler LR. Clinical trials of stroke therapy: which cells, which patients?. Stroke 2009, 40:S149-S151. 10.1161/STROKEAHA.108.533208, 19064792.
34. Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006, 355:1730-1735. 10.1056/NEJMhpr063086, 17050899.
35. International Society for Stem Cell Research Homepage [http://www.isscr.org], International Society for Stem Cell Research.
36. International Cellular Medicine Society Homepage [http://www.cellmedicinesociety.org], International Cellular Medicine Society.
37. Lee PH, Kim JW, Bang OY, Ahn YH, Joo IS, Huh K. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008, 83:723-730. 10.1038/sj.clpt.6100386, 17898702.
38. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, Hsu SC, Smith J, Prockop DJ. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004, 9:747-756. 10.1016/j.ymthe.2004.02.012, 15120336.
39. Mannello F, Tonti GA. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold!. Stem Cells 2007, 25:1603-1609. 10.1634/stemcells.2007-0127, 17395775.
40. Boncoraglio GB, Bersano A, Candelise L, Reynolds BA, Parati EA. Stem cell transplantation for ischemic stroke. Cochrane Database Syst Rev 2010, 9:CD007231.
41. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Biophys Res Commun 2007, 358:948-953. 10.1016/j.bbrc.2007.05.054, 17521616.
42. Pasha Z, Wang Y, Sheikh R, Zhang D, Zhao T, Ashraf M. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 2008, 77:134-142.
43. Borlongan CV, Hadman M, Sanberg CD, Sanberg PR. Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 2004, 35:2385-2389. 10.1161/01.STR.0000141680.49960.d7, 15345799.
44. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Regeneration of the ischemic brain by engineered stem cells: fuelling endogenous repair processes. Brain Res Rev 2009, 61:1-13. 10.1016/j.brainresrev.2009.03.003, 19348860.
45. Bang OY, Jin KS, Hwang MN, Kang HY, Kim BJ, Lee SJ, Kang S, Hwang YK, Ahn JS, Sung KW. The effect of CXCR4 overexpression on mesenchymal stem cell transplantation in ischemic stroke. Cell Med 2012, 4:65-76.
46. Schaller B, Graf R. Cerebral ischemic preconditioning. An experimental phenomenon or a clinical important entity of stroke prevention?. J Neurol 2002, 249:1503-1511. 10.1007/s00415-002-0933-8, 12420088.
47. Maulik N, Yoshida T, Engelman RM, Deaton D, Flack JE, Rousou JA, Das DK. Ischemic preconditioning attenuates apoptotic cell death associated with ischemia/reperfusion. Mol Cell Biochem 1998, 186:139-145. 10.1023/A:1006883717174, 9774195.
48. Wegener S, Gottschalk B, Jovanovic V, Knab R, Fiebach JB, Schellinger PD, Kucinski T, Jungehulsing GJ, Brunecker P, Muller B, Banasik A, Amberger N, Wernecke KD, Siebler M, Rother J, Villringer A, Weih M. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke 2004, 35:616-621. 10.1161/01.STR.0000115767.17923.6A, 14963288.
49. Haider H, Ashraf M. Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 2008, 45:554-566. 10.1016/j.yjmcc.2008.05.004, 2670565, 18561945.
50. Kohin S, Stary CM, Howlett RA, Hogan MC. Preconditioning improves function and recovery of single muscle fibers during severe hypoxia and reoxygenation. Am J Physiol Cell Physiol 2001, 281:C142-C146.
51. Werner M, Mayleben T, Van Bokkelen G. Autologous cell therapies: the importance of regulatory oversight. Regen Med 2012, 7:100-103. 10.2217/rme.12.90, 23210820.
52. Zacharek A, Shehadah A, Chen J, Cui X, Roberts C, Lu M, Chopp M. Comparison of bone marrow stromal cells derived from stroke and normal rats for stroke treatment. Stroke 2010, 41:524-530. 10.1161/STROKEAHA.109.568881, 2847444, 20056925.
53. Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation therapy for stroke. Stroke 2007, 38:817-826. 10.1161/01.STR.0000247888.25985.62, 17261746.
54. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2009, 72:1310-1315. 10.1212/01.wnl.0000341308.73506.b7, 2677490, 19092107.
55. Lees KR, Bath PM, Schellinger PD, Kerr DM, Fulton R, Hacke W, Matchar D, Sehra R, Toni D. Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 2012, 43:1163-1170. 10.1161/STROKEAHA.111.641423, 22426313.
56. Demeurisse G, Demol O, Robaye E. Motor evaluation in vascular hemiplegia. Eur Neurol 1980, 19:382-389. 10.1159/000115178, 7439211.
57. Berglund K, Fugl-Meyer AR. Upper extremity function in hemiplegia. A cross-validation study of two assessment methods. Scand J Rehabil Med 1986, 18:155-157.
58. Mathiowetz V, Wiemer DM, Federman SM. Grip and pinch strength: norms for 6- to 19-year-olds. Am J Occup Ther 1986, 40:705-711. 10.5014/ajot.40.10.705, 3777107.
59. Desrosiers J, Bravo G, Hebert R, Dutil E, Mercier L. Validation of the box and block test as a measure of dexterity of elderly people: reliability, validity, and norms studies. Arch Phys Med Rehabil 1994, 75:751-755.
60. Collen FM, Wade DT, Bradshaw CM. Mobility after stroke: reliability of measures of impairment and disability. Int Disabil Stud 1990, 12:6-9. 10.3109/03790799009166594, 2211468.
61. Cheeran B, Talelli P, Mori F, Koch G, Suppa A, Edwards M, Houlden H, Bhatia K, Greenwood R, Rothwell JC. A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. J Physiol 2008, 586:5717-5725. 10.1113/jphysiol.2008.159905, 2655403, 18845611.
62. Siironen J, Juvela S, Kanarek K, Vilkki J, Hernesniemi J, Lappalainen J. The Met allele of the BDNF Val66Met polymorphism predicts poor outcome among survivors of aneurysmal subarachnoid hemorrhage. Stroke 2007, 38:2858-2860. 10.1161/STROKEAHA.107.485441, 17761923.
63. Vilkki J, Lappalainen J, Juvela S, Kanarek K, Hernesniemi JA, Siironen J. Relationship of the Met allele of the brain-derived neurotrophic factor Val66Met polymorphism to memory after aneurysmal subarachnoid hemorrhage. Neurosurgery 2008, 63:198-203. 10.1227/01.NEU.0000320382.21577.8E, 18797348.
64. Kim SJ, Moon GJ, Cho YH, Kang HY, Hyung NK, Kim D, Lee JH, Nam JY, Bang OY. Circulating mesenchymal stem cells microparticles in patients with cerebrovascular disease. PLoS ONE 2012, 7:e37036. 10.1371/journal.pone.0037036, 3352849, 22615882.
65. Cheung K, Kaufmann P. Efficiency perspectives on adaptive designs in stroke clinical trials. Stroke 2011, 42:2990-2994. 10.1161/STROKEAHA.111.620765, 3183258, 21885845.